Complement Literature

2015

Peffault de Latour R, et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood 2015;125:775-83.

Bajic,G et al. Complement activation, regulation, and molecular basis for complement-related diseases. EMBO Journal 2015;34:2735–57,

Sfyroera G, et al. Rare loss-of-function mutation in complement component C3 provides insight into molecular and pathophysiological determinants of complement activity. J Immunol. 2015; 194:3305-16.

Frémeaux-Bacchi V, Legendre C M. The emerging role of complement inhibitors in transplantation. Kidney Int 2015;88:967-73

Mathern DR, Heeger PS. Molecules Great and Small: The Complement System. Clin J Am Soc Nephrol 2015;10:1636-50.

Risitano A M. Dissecting complement blockade for clinic use. BLOOD 2015;125:742-4.

Wang J, et al. Complement Activity is Altered in Obstructive Sleep Apnea. Am J Respir Crit Care Med 2015;191:A2146.

Haapasalo K, et al. Complement Factor H Binds to Human Serum Apolipoprotein E and Mediates Complement Regulation on High Density Lipoprotein Particles. J Biol Chem. 2015;290:28977-87.

Berg, A et al. Complement Activation Correlates with Disease Severity and Contributes to Cytokine Responses in Plasmodium falciparum Malaria. J Infect Dis 2015; 212:1835-40.

Blom A et al. Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation. Mol Immunol 2015; 66:164-70.

Egge, K. H., et al.The anti-inflammatory effect of combined complement and CD14 inhibition is preserved during escalating bacterial load. Clin Exp Immuno 2015;181:457–67.

Hein, E., et al. Heparin-coated cardiopulmonary bypass circuits selectively deplete the pattern recognition molecule ficolin-2 of the lectin complement pathway in vivo. Clin Exp Immunol 2015;179:294–9.

Hovland A et al. The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis. Atherosclerosis 2015; 241: 480-94.

Lappegård K T A et al. Terapeutisk komplementhemming – fra eksperimentell til klinisk medisin. Therapeutic complement inhibition – from experimental to clinical medicine Tidsskr Nor Legeforen 2015;135:1745?–?9.

Smedbraten, Y V et al. High Ficolin-3 Level at the Time of Transplantation Is an Independent Risk Factor for Graft Loss in Kidney Transplant Recipients. Transplantation 2015;99:791-6.

Volokhina E B et al. Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo BLOOD 2015;126:278-9.

Volokhina E B et al.Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clin Immunol 2015;160:237–43.

Merle NS, et al. Complement system part II: role in immunity. Front. Immunol 2015; 6:257.

Salmon JEet al.Complement Activation Predicts Adverse Pregnancy Outcome in Patients with SLE and/or aPL Antibodies [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10).

Brandstetter C et al. Complement component C5a primes retinal pigment epithelial cells for inflammasome activation by lipofuscin-mediated photooxidative damage. Journal of Biological Chemistry 2015; 290: 31189-98.

Li L, et al. Review on complement analysis method and the roles of glycosaminoglycans in the complement system. Carbohydr Polym 2015;134:590-7.

Melis JP et al. Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics.Mol Immunol. 2015;67:117-30.

2014

Cataland S R et al. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood. 2014;123:3733-38

Csuka D et al. Activation of the ficolin-lectin pathway during attacks of hereditary angioedema. J Allergy Clin Immunol. 2014 Jul 16. [Epub ahead of print]

Cugno M et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost. 2014; 12:1440-8

Grumach A S, Kirschfink M.  Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Molecular Immunology 2014; 61: 110–117

Grumach A S et al. Complement profile in neonates of different gestational ages. Scand J Immunol. 2014;79:276-81

Koscielska-Kasprzak K et al. The Complement Cascade and Renal Disease. Arch. Immunol. Ther. Exp. 2014; 62:47–57

Ma R et al. The Alternative Pathway of Complement Activation May Be Involved in the Renal Damage of Human Anti-Glomerular Basement Membrane Disease. PLOS One 2014; 9: e91250; Open access

Noris M et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 2014;124:1715-26 

Zanier ER et al. Ficolin-3-mediated lectin complement pathway activation in patients with subarachnoid hemorrhage. Neurology. 2014;82:126-34

Wehling C, Kirschfink M. Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis. J Thromb Haemost. 2014;12:1437-9

2013

Heinen S et al. Monitoring and modeling treatment of atypical hemolytic uremic syndrome. Molecular Immunology 54 (2013) 84–88

Ricklin D, Lambris JD. Progress and Trends in Complement Therapeutics. Adv Exp Med Biol. 2013;735:1-22

Salvador Morales C et al. Complement Activation (Chapter 11). Handbook of Immunological Properties of Engineered Nanomaterials, 2013

Severino et al. An Integrated Approach Based on Multiplexed Protein Array and iTRAQ Labeling for In-Depth Identification of Pathways Associated to IVF Outcome. PLOS ONE:2013:Volume 8: Issue 10: e77303

Slade C et al. Deficiency in Complement Factor B. N Engl J Med 369;17, 1667-1669: 2013

Tijink M et al. Development of novel membranes for blood purification therapies based on copolymers of N-vinylpyrrolidone and n-butylmethacrylate. Chem. B, 2013, 1, 6066–6077

2012


Barthel D et al. Plasminogen Is a Complement Inhibitor. JBC, 2012; 287:18831-18842

Brunner J et al. Analysis of the classical, alternative, and mannose binding lectin pathway of the complement system in the pathogenesis of oligoarticular juvenile idiopathic arthritis. Rheumatol Int (2012) 32:1815–1818

Cazander G et al. Maggot excretions affect the human complement system. Wound Repair Regen. 2012; 20: 879-86 (ABSTRACT)

DeAngelis RA et al. Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. Immunobiology. 2012 ;217:1097-105

Idorn T et al. Anti-glomerular basement membrane glomerulonephritis and thrombotic microangiopathy in first degree relatives; a case report. BMC Nephrology 2012; 13:64

Inoshita H et al. An analysis of functional activity via the three complement pathways during hemodialysis sessions: a new insight into the association between the lectin pathway and C5 activation. Clin Kidney J (2012) 5: 401–404

Li Y et al. Label-free quantitative proteomic analysis reveals dysfunction of complement pathway in peripheral blood of schizophrenia patients: evidence for the immune hypothesis of schizophrenia (ABSTRACT). Mol. BioSyst., 2012,8, 2664-2671

Mika A et al. Complement Inhibitors from Scabies Mites Promote Streptococcal Growth – A Novel Mechanism in Infected Epidermis? PLoS Negl Trop Dis 6(7): e1563

Nilsson B et al. Complement Diagnostics: Concepts, Indications, and Practical Guidelines. Clinical and Developmental Immunology, Volume 2012, Article ID 962702, 11 pages

Prior N et al. Development of a disease-specific quality oflife questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): Spanish multi-centre research project. Health and Quality of Life Outcomes 2012, 10:82

Prohászka Z et al. The use of ‘real-time’ complement analysis to differentiate atypical haemolytic uraemic syndrome from other forms of thrombotic microangiopathies. British J Haematology, 2012, 158, 415–429

Sethi S et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney International (2012) 82, 465–473

Tudoran R & Kirschfink M. Modern complement analysis: indications, methods and outlook. J Lab Med 2012;36:XX. doi10.1515/labmed-2012-0009.et.

2011


Barratt-Due A et al. Ornithodoros moubata Complement Inhibitor Is an Equally Effective C5 Inhibitor in Pigs and Humans. J Immunol, 2011;187: 000–000

Bergseth G et al. Artificial Surface-Induced Inflammation Relies on Complement Factor 5: Proof From a Deficient Person. Ann Thorac Surg. 2011; 91: 527–533.

Ehrnthaller C et al. New insights of an old defense system: Structure, function, and clinical relevance of the complement system. Mol Med 2011;17: 317-329.

Fridkis-Hareli M et al. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases. Blood. 2011;118:4705-4713

Grimnes G et al. Recurrent meningococcal sepsis in a presumptive immunocompetent host shown to be complement C5 deficient—a case report. APMIS 2011

Harboe M et al. Advances in assay of complement function and activation. Adv Drug Deliv Rev 2011;xx:xx. 10.1016/j.addr.2011.05.010

Ilyas R et al. High Glucose Disrupts Oligosaccharide Recognition Function Via Competitive Inhibition: A Potential Mechanism for Immune Dysregulation in Diabetes Mellitus. Immunobiology 2011; 216: 126–131

Martel C et al. Requirements for Membrane Attack Complex Formation and Anaphylatoxins Binding to Collagen-Activated Platelets. PLoS One 2011; 6: e18812

Oberbach A et al. Combined Proteomic and Metabolomic Profiling of Serum Reveals Association of the Complement System with Obesity and Identifies Novel Markers of Body Fat Mass Changes. J. Proteome Res. 2011, 10, 4769–4788

Reusz G.S. et al. Diagnosis and Classification of Hemolytic Uremic Syndrome: The Hungarian Experience. Transplantation Proceedings, 43, 1247–1249 (2011)

Senbagavalli P et al. Heightened Measures of Immune Complex and Complement Function and Immune Complex–Mediated Granulocyte Activation in Human Lymphatic Filariasis. Am. J. Trop. Med. Hyg. 2011; 85: 89–96

Sethi S et al. Proliferative Glomerulonephritis Secondary to Dysfunction of the Alternative Pathway of Complement. Clin J Am Soc Nephrol 6: 1009–1017, 2011

van Werkhoven M.B. et al.Increased renal C5a receptor expression and systemic complement activation in brain dead donors. MOL IMMUNOL 2011; 48(14):1729-1729

2010

Castellano G, et al. Therapeutic Targeting of Classical and Lectin Pathways of Complement Protects from Ischemia-Reperfusion-Induced Renal Damage. The American Journal of Pathology, Vol. 176, No. 4, April 2010

Hamad I et al. Distinct Polymer Architecture Mediates Switching of Complement Activation Pathways at the Nanosphere_Serum Interface: Implications for Stealth Nanoparticle Engineering. acsnano 2010; 4: 6629–6638

Inoshita H et al. Complement in patients receiving maintenance hemodialysis: functional screening and quantitative analysis. BMC Nephrology 2010; 11:34

Kadam A P et al. Identification of Complin, a Novel Complement Inhibitor that Targets Complement Proteins Factor B and C2. The Journal of Immunology, 2010, 184: 000–000

Kocsis A et al. Selective Inhibition of the Lectin Pathway of Complement with Phage Display Selected Peptides against Mannose-Binding Lectin-Associated Serine Protease (MASP)-1 and -2: Significant Contribution of MASP-1 to Lectin Pathway Activation. J Immunol 2010; 185:4169-4178

Maga T K et al. A novel deletion in the RCA gene cluster causes atypical hemolytic uremic syndrome. Nephrol Dial Transplant (2010) 1 of 3, doi: 10.1093/ndt/gfq658

Orth D et al. EspP, a Serine Protease of Enterohemorrhagic Escherichia coli, Impairs Complement Activation by Cleaving Complement Factors C3/C3b and C5. INFECTION AND IMMUNITY 2010; 78: 4294–4301

Zimmerhackl L B et al. Prophylactic Eculizumab after Renal Transplantation in Atypical Hemolytic–Uremic Syndrome. The New England Journal of Medicine 362;18, May 6, 2010

2009


Botto et al. Complement in human disease: Lessons from complement deficiencies. Mol Immunol 2009;XX: XX. doi:10.1016/j.molimm.2009.04.029.

Ceribelli A et al. Complement Cascade in Systemic Lupus Erythematosus Analyses of the Three Activation Pathways. Ann. N.Y. Acad. Sci. 2009; 1173: 427–434

Lappegård K T et al. Human genetic deficiencies reveal the roles of complement in the inflammatory network: Lessons from nature. PNAS 2009; 106: 15861–15866

Nyakoe N K et al. Consumption in children with Plasmodium falciparum Malaria. Malaria Journal 2009, 8:7 doi:10.1186/1475-2875-8-7

Salvesen B, Mollnes TE. Pathway-specific complement activity in pigs evaluated with a human functional complement assay. Molecular Immunology 2009; 46: 1620-1625

2008


Burman J D et al. Interaction of Human Complement with Sbi, a Staphylococcal Immunoglobulin-binding Protein - INDICATIONS OF A NOVEL MECHANISM OF COMPLEMENT EVASION BY STAPHYLOCOCCUS AUREUS. JBC 2008; 283: 17579–17593

Hamad I et al. Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Mol Immunol 2008; 45: 3797–3803

Kimura Y et al. Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement. Blood 2008; 111: 732-740

Kuo C-F et al. Degradation of Complement 3 by Streptococcal Pyrogenic Exotoxin B Inhibits Complement Activation and Neutrophil Opsonophagocytosis. Infection and Immunity 2008; 76: 1163–1169

Upadhyay A et al. Structure-Function Analysis of the C3 Binding Region of Staphylococcus aureus Immune Subversion Protein Sbi. JBC 2008; 283: 22113–22120

Varga L et al. Depressed activation of the lectin pathway of complement in hereditary angioedema. Clin Exp Immunol 2008; 153: 68–74

2007


Manuel  O et al. Meningococcal disease in a kidney transplant recipient with mannose-binding lectin deficiency. Transplant Infectious Disease 2007; 9: 214-218

Mollnes TE et al. Complement analysis in the 21st century. Mol Immunol 2007;44: 3838-3849.

Waage Nielsen E et al. Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement. Mol Immunol 2007; 44: 1819–1826

2005


Fevang B et al. Common variable immunodeficiency and the complement system; low mannose-binding lectin levels are associated with bronchiectasis. Clin Exp Immunol 2005; 142:576–584

Seelen MA et al. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Meth 2005;296: 187-198.

 aHUS

Euro Diagnostica Headquarters

Mailing address:
P.O. Box 50117
SE-202 11 Malmö
SWEDEN

Visiting address:
Lundavägen 151
Malmö
SWEDEN
VAT No. SE556564064501

 

Phone: +46 40 53 76 00
Fax: +46 40 43 22 88
info@eurodiagnostica.com

Please mail your order to:
order@eurodiagnostica.com

Please visit our contact section for information about local offices around the world

Shortcuts and important links

Share on Google+ Share on LinkedIn Share on Twitter Share on Facebook



© 2000-2016 Euro Diagnostica AB
All rights reserved.